Compound Cordyceps Sinensis Liposome Oral Liquid in Treatment of Patients with Chronic Hepatitis B
Sun Wanfeng, Sun Rongling, Jiang Weiling, et al . (Infectious Hospital of Yantai, Shandong 264001,P.R.China)
Objective: To study the therapeutic effects of compound Cordyceps sinensis liposome oral liquid in treatment of chronic hepatitis B. Method: The tested group(52 cases) was given the liposome oral liquid containing cordyceps sinensis, Astragali L and Salvia miltiorrhiza , the controlled group(40 cases) was given the other ordinary drugs of protecting liver.Result: Three months after the treatment, the rate of serum ALT back to normal in the tested group was 65.4% , the controlled group was 42.5% ( P 0.05 ). The negative conversion rate of serum HBeAg were 65.4% and 42.5% , respectively( P 0.05 ); the negative conversion rate of HBeAg were 34.6% and 2.5% , respectively( P 0.001 ); the negative conversion rate of HBV DNA were 42.3% and 5%, respectively ( P 0.001 ). Before and after therapy, the level declining of serum HA, IV C, LN had markedly difference in the tested group ( P 0.01 ), but there was no significant difference in the controlled group ( P 0.05% ). Conclusion: The compound Cordyceps sinensis liposome oral liquid has a good curative effect on chronic hepatitis B, it can improve the liver function, resist virus, and prevent liver fibrosis.
【CateGory Index】： R512.62